Costs and Access Barriers to Ondansetron in the US
This cross-sectional study compares the use of management tools and plan-level total costs for oral ondansetron between Part D independent prescription drug plans and Medicare Advantage prescription drug plans.
Authors
- Ryan David Nipp (ORCID: https://orcid.org/0000-0002-4577-3248)
- Joshua M. Liao (ORCID: https://orcid.org/0000-0002-9788-9074)
- K. Robin Yabroff (ORCID: https://orcid.org/0000-0003-0644-5572)
- Xin Hu (ORCID: https://orcid.org/0000-0003-1097-3300)
- Changchuan Jiang (ORCID: https://orcid.org/0000-0002-7392-4154)
- Ya‐Chen Tina Shih (ORCID: https://orcid.org/0000-0001-7290-3864)
- Xuesong Han (ORCID: https://orcid.org/0000-0001-7159-7949)
Institutions
- American Cancer Society (US)
- Emory University (US)
- University of California, Los Angeles (US)
- University of Oklahoma Health Sciences Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.43978
- Citations
- 3
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 1.72